Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be admitted to the ICU~* Have digital ischemia and~* Be on a vasopressor infusion~Exclusion Criteria:~* Patients with a history of systemic sclerosis~* Patients actively receiving aminoglycoside antibiotics - aminoglycosides may potentiate the effect of Botox~* Patients who have previously received botulinum toxin (A or B) injections~* Patients with a history of disorders of neuromuscular transmission (e.g myasthenia gravis, Lambert-Eaton, etc.) - Botox may have a lasting effect in these patients given their disorder~* Patients with clinical evidence of an infection in either forearm or hand~* Patients with a history of sensitivity to albumin - Botox is sold in powder form and there is albumin in the formulation~* Pregnancy - Botox is a class C medication~* Rheumatoid Arthritis~* Upper extremity arterio-venous graft or fistula~* Digital necrosis~* History of hand amputation~* Patients whom the intensive care attending physician deems will expire within 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botox injection (Type: EXPERIMENTAL): Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia

Based on this trial design, predict the completion outcome and termination type (if applicable).